Pharmacoepigenetics of Acute Myeloid Leukemia

Abstract The discovery of the genetic alterations that occur in acute myeloid leukemia (AML) and the ability, using modern molecular techniques, to profile the genomic and epigenomic landscape has provided new treatment avenues and therapeutic targets for the disease. Advances in biotechnology have led to the availability of molecular agents specifically directed at these targets. In recent years these agents have been made available clinically for treating patients with AML. In this chapter we will provide an overview of the regulatory mechanisms in epigenetics in AML and discuss the pharmacoepigenetics of the disease. We will survey the results of clinical trials using epigenetic modifiers as monotherapy, in conjunction with combination chemotherapy, or in dual epigenetic targeting studies. We will also discuss the outcome of patients who received epigenetic modifiers as primers of induction chemotherapy for AML. Finally, we will explore how targeting epigenetic mechanisms might enhance the immunotherapeutics of AML.

• Publication year

  2019

• Venue

  Pharmacoepigenetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-0-12-813939-4.00016-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

  2017cited by this paper
• Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study

  2017cited by this paper
• Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?

  2017cited by this paper
• Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

  2017cited by this paper
• A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML

  2017cited by this paper
• Molecular targeting in acute myeloid leukemia

  2017cited by this paper
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

  2017cited by this paper
• A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

  2017cited by this paper
• A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

  2017cited by this paper
• Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

  2016cited by this paper
• SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

  2016cited by this paper
• Epigenetic regulators and their impact on therapy in acute myeloid leukemia

  2016cited by this paper
• A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations

  2016cited by this paper
• A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells

  2016cited by this paper
• Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

  2016cited by this paper
• Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

  2016cited by this paper
• Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

  2016cited by this paper
• Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

  2016cited by this paper
• Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia

  2015cited by this paper
• Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.

  2015cited by this paper
• BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

  2015cited by this paper
• The Small Molecule Img-98, a Potent and Selective Inhibitor of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation Effects of ATRA in a Pre-Clinical Model of AML

  2015cited by this paper
• Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

  2015cited by this paper
• Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

  2015cited by this paper
• A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

  2014cited by this paper
• Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

  2014cited by this paper
• Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

  2014cited by this paper
• Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

  2014cited by this paper
• Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

  2014cited by this paper
• Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

  2014cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.

  2012cited by this paper
• Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

  2012cited by this paper
• Cancer‐testis antigen expression and its epigenetic modulation in acute myeloid leukemia

  2011cited by this paper
• Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

  2011cited by this paper
• DNMT3A mutations in acute myeloid leukemia.

  2010cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Epigenetic changes in the myelodysplastic syndrome.

  2010cited by this paper
• Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

  2010cited by this paper
• Structural Basis for Acetylated Histone H4 Recognition by the Human BRD2 Bromodomain*

  2010cited by this paper
• Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010.

  2010cited by this paper
• Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

  2010cited by this paper
• High-dose daunorubicin in older patients with acute myeloid leukemia.

  2009cited by this paper
• Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.

  2008cited by this paper
• Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.

  2007cited by this paper
• A yeast two‐hybrid system using Sp17 identified Ropporin as a novel cancer–testis antigen in hematologic malignancies

  2007cited by this paper
• mRNA expression of MAGE-A3 gene in leukemia cells.

  2007cited by this paper
• Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses

  2006cited by this paper
• Age and acute myeloid leukemia.

  2006cited by this paper
• Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1

  2006cited by this paper
• hDOT1L links histone methylation to leukemogenesis.

  2005cited by this paper
• The Spermatozoa Protein, SLLP1, Is a Novel Cancer–Testis Antigen in Hematologic Malignancies

  2004cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cited by this paper
• Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation

  2004cited by this paper
• Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies.

  2003cited by this paper
• CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

  2002cited by this paper
• Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells

  1999cited by this paper
• Expression of testicular genes in haematological malignancies

  1999cited by this paper
• Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.

  1999cited by this paper
• The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.

  1999cited by this paper
• PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells

  1998cited by this paper
• Alterations in DNA methylation: a fundamental aspect of neoplasia.

  1998cited by this paper
• THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS

  1996cited by this paper
• Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes.

  1994cited by this paper
• Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.

  1989cited by this paper
• Cellular differentiation, cytidine analogs and DNA methylation.

  1980cited by this paper

• No citing papers are available for this paper.